|
Abnormal behavior
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute alcoholic liver disease
|
0.200 |
Therapeutic
|
disease |
RGD |
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
|
27939985 |
2017 |
|
Adenoviral infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, we expressed carnitine palmitoyltransferase 1AM (CPT1AM), a permanently active mutant form of CPT1A (the rate-limiting enzyme in FAO), in a rat brown adipocyte (rBA) cell line through adenoviral infection.
|
27438137 |
2016 |
|
Adrenal Gland Pheochromocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria.
|
28671672 |
2017 |
|
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We evidenced that high grade glioblastoma is associated with increased level of ZFP57, a protein involved in gene imprinting, and aberrant expression of CPT1A and CPT1C, regulators of fatty acid oxidation.
|
24618825 |
2014 |
|
Adult Liver Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The up-regulation of expression of hepatic genes related to liver steatosis (CPT1A, FASN, LEPR, RXRA, IGFBP1, PPARGC1A and SLC2A4) was detected in our rhesus model, as was the down-regulation of such genes (CYP7A1, HMGCR, GCK and PNPLA3) and the up-regulation of expression of hepatic genes related to liver cancer (E2F1, OPCML, FZD7, IGFBP1 and LEF1).
|
26442469 |
2015 |
|
Alloxan Diabetes
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes.
|
16123366 |
2005 |
|
Alveolar rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CPT1A may represent a novel therapeutic target for the treatment of ARMS.
|
22533991 |
2012 |
|
Alzheimer's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Similarly, treatment of a mouse model of AD, the APP/PS1-mice, with GW0742 increased the expression of Cpt1a and concomitantly reversed memory deficits in a fear conditioning test.
|
30453390 |
2019 |
|
Anhedonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This indicate that alteration in metabolism is pivotal in the pathogenesis of depression, since CPT1 blockage is highly efficient in treating anhedonia and inflammation, thereby opening up for a novel class of antidepressant medication.
|
28526869 |
2017 |
|
Arthritis, Psoriatic
|
0.020 |
Biomarker
|
disease |
BEFREE |
Additionally, 1,25(OH)2D significantly increased ATP levels and gene expression related to mitochondrial function such as carnitine palmitoyltransferase 1 (CPT1), peroxisome proliferator-activated receptor α (PPARα), very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain acyl-CoA dehydrogenase (LCAD), medium-chain acyl-CoA dehydrogenase (MCAD), uncoupling protein 2 (UCP2), and UCP3 and the vitamin D pathway including 25-dihydroxyvitamin D3 24-hydroxylase (CYP24) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27) in PA-treated C2C12 myotubes.
|
31744213 |
2019 |
|
Arthritis, Psoriatic
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Results showed that compared with the PA-alone group, 100 μM capsiate inhibited lipid accumulation, decreased TG (0.0562 ± 0.0142 vs 0.0381 ± 0.0055 mmol/g of protein; P = 0.024) and TC (0.1087 ± 0.0037 vs 0.0359 ± 0.0059 mmol/g of protein; P = 0.000) levels, and increased the HDL-C level (0.0189 ± 0.0067 vs 0.1050 ± 0.0106 mmol/g of protein; P = 0.000) and glycogen content (0.0065 ± 0.0007 vs 0.0146 ± 0.0008 mg/10<sup>6</sup> cells; P = 0.000) of PA-treated HepG2 cells; 100 μM capsiate also upregulated the level of CD36 ( P = 0.000), phosphorylation of ACC ( P = 0.034), and expression of CPT1 ( P = 0.013) in PA-treated HepG2 cells, leading to an enhancement of lipid metabolism.
|
29886733 |
2018 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.
|
29304378 |
2018 |
|
Breast Carcinoma
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
These findings provide evidence of the CPT1 variant 2 involvement in breast cancer survival, cell death escape and invasion.
|
26799588 |
2016 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.
|
25151356 |
2014 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
CPT1A (carnitine palmitoyltransferase 1a) has been reported to play a critical role in breast cancer progress.
|
29940537 |
2018 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Enhanced CPT1A/CPT2 expression was detected in the recurrent human breast cancers and associated with a worse prognosis in breast cancer patients.
|
31803610 |
2019 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study indicate that NEAT1 promotes the expression of CPT1A by inhibiting miR‑107 to improve the progression of BC cells; therefore, NEAT1 is a potential therapeutic target of BC.
|
31485672 |
2019 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
PRL stimulation increased the expression of CPT1A (liver isoform) at the mRNA and protein levels in both breast cancer cell lines, but not in 184B5 cells.
|
21294903 |
2011 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
We have studied the tumor-specific modulation of CPT1 and FAS in human colorectal cancer (n = 11) and breast carcinomas (n = 24).
|
18253084 |
2007 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
A doxycycline-inducible breast cancer cell line model overexpressing the rate-limiting enzyme in FAO, carnitine palmitoyl transferase 1A (CPT1A) was generated and analysed to confirm the association between FAO and cancer-associated characteristics in vitro.
|
30092766 |
2018 |
|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
When administrated alone, caffeine (5 and 50 mg/kg) and 8-CPT (1 and 5 mg/kg) significantly decreased seizure threshold, while 100 mg/kg of caffeine, SCH-442416 or sildenafil did not change it.
|
30391360 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Increasing evidence has indicated that CPT1A plays an important role in carcinogenesis.
|
30016793 |
2018 |
|
Carcinogenesis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
The proliferation and tumorigenesis in V600E melanoma were decrease after CPT1A knockdown.
|
27793752 |
2016 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The peculiar localization of CPT1 in the nuclei of human carcinomas and the disclosed functional link between nuclear CPT1 and HDAC1 propose a new role of CPT1 in the histonic acetylation level of tumors.
|
18253084 |
2007 |